Company news
Immunitybio, Inc. (NASDAQ:IBRX) news
Immunitybio, Inc. news releases on 6ix. Latest, Aug 13, 2025: ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients…
Press releases — page 2
ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy
August 12, 2025
ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients
August 10, 2025
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code
August 4, 2025
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
July 24, 2025
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
July 24, 2025
UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
July 6, 2025
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
June 3, 2025
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
June 1, 2025
ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East
May 26, 2025
ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code
May 11, 2025
ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025
May 4, 2025
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up
April 27, 2025
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
April 20, 2025
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
April 14, 2025
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
April 7, 2025
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
April 6, 2025
ImmunityBio to Host Investor Day
March 25, 2025
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
March 12, 2025
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
March 2, 2025
ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer
February 26, 2025
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
February 18, 2025
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
February 12, 2025
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
January 28, 2025
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
January 26, 2025
ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom
January 14, 2025
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency
January 14, 2025
ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective
January 5, 2025
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
December 10, 2024
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
December 9, 2024
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
November 20, 2024
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
November 18, 2024
ImmunityBio Reports Third-Quarter 2024 Financial Results
November 11, 2024
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
October 23, 2024
ImmunityBio to Participate in the Jefferies London Healthcare Conference
October 20, 2024
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
September 8, 2024
ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
August 11, 2024
ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer
August 5, 2024
ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
June 19, 2024
ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
June 6, 2024
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
May 6, 2024
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
May 1, 2024
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
April 29, 2024
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
April 24, 2024
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
April 21, 2024
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
March 5, 2024
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
March 4, 2024
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
February 20, 2024
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
February 4, 2024
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
January 1, 2024
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
November 15, 2023